FTSE 100 today: Stocks fall, pound climbs; Rightmove, IAG slumps, ITV soars
Investing.com -- HALEON PLC (LON:HLN), a global leader in consumer health, on Thursday reaffirmed its full-year guidance despite delivering mixed regional performance in the third quarter of 2025.
The company maintained its organic revenue growth forecast of around 3.5% for fiscal year 2025, slightly ahead of analyst consensus of 3.4%.
The consumer health giant reported that while volume and mix fell short of expectations in the third quarter, stronger-than-anticipated price growth helped offset the weakness. North America emerged as a bright spot, exceeding growth forecasts and capturing approximately 100 basis points of market share in the United States.
The company expressed confidence in returning to growth next year as inventory levels at retail partners normalize by year-end.
Latin America continued its positive trajectory with low-single-digit growth, driven by strong performance in Colombia and Mexico, which compensated for declining sales in Brazil.
However, Asia-Pacific results came in softer than expected, with North Asia experiencing a low-single-digit decline attributed to retail stocking patterns that management expects to reverse in the fourth quarter. India stood out as a particularly robust market, delivering double-digit growth.
"We remain confident in our ability to deliver on our full-year guidance, supported by the strength of our brands and our geographic diversification," said Dawn Allen, Chief Financial Officer at Haleon.
Looking ahead, Haleon maintained its high-single-digit organic operating profit growth outlook for 2025, compared to consensus expectations of 9.3%. The company’s guidance assumes normal cold and flu season conditions. Haleon also reaffirmed its mid-term organic revenue growth target of 4-6%.